Zevra appoints Alicia Secor to board; director Wendy Dixon retires

ZEVRA THERAPEUTICS, INC.

Director Wendy Dixon resigned effective Dec 2, 2025; no disagreement with company operations.
Alicia Secor appointed to board as Class I director, term expiring at 2028 annual meeting.
Secor will serve on Compensation and Audit committees; compensation per director policy.
Secor brings 30+ years life sciences experience, including CEO roles at Atalanta and Juniper.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.